Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical Practice
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Use of continuous glucose monitoring (CGM) is recognized as a valuable component of diabetes self-management and is increasingly considered a standard of care for individuals with diabetes who are treated with intensive insulin therapy. As the clinical use of CGM technology expands, consistent and standardized glycemic metrics and glucose profile visualization have become increasingly important. A common set of CGM metrics has been proposed by an international expert panel in 2017, including standard definitions of time in ranges, glucose variability, and adequacy of data collection. We describe the core CGM metrics, as well as the standardized glucose profile format consolidating 2 weeks of CGM measurements, referred to as the ambulatory glucose profile (AGP), which was also recommended by the CGM expert panel. We present an updated AGP report featuring the core CGM metrics and a visualization of glucose patterns that need clinical attention. New tools for use by clinicians and patients to interpret AGP data are reviewed. Strategies based on the authors' experience in implementing CGM technology across the clinical care spectrum are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 5×
“We now know that time in target range (TIR) (70–180 mg/dL) alone is not an 25 With consensus on the definition for TIR, 18 the strong correlation of TIR with microvascular complications has been published.”
InfluentialSelf-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Self-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793 · cited 3×
“27 Beck et al. have also presented data based on post hoc analysis of the same DCCT data set linking biochemical glucose of < 70 and < 54 mg/dL with ‘‘increased risk for severe hypoglycemia.’’”
Self-citationLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Self-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationBeck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“6,11 As in T1D, individuals with T2D on intensive insulin regimens can benefit from the use and availability of CGM for glycemic monitoring.”
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationEffects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin
Bry, L., Chen, P. C., & Sacks, D. B. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.2.153 · Cited by 523 · cited 1×
“Moreover,HbA1c is an unreliable measure in multiple settings; certain conditions such as anemia, 20 hemoglobin-opathies, 21 iron deficiency, 22 and pregnancy 23 can confound test results.”
Lu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517
The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
Self-citationWhite, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390 · cited 1×
“42 We favor the use of CV over standard deviation (SD) to assess glucose variability as the CV calculation accounts for an individual’s mean glucose, which SD does not.”
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
HbA1c levels are significantly lower in early and late pregnancy
Nielsen, L. R., Ekbom, P., Damm, P., Glümer, C., Frandsen, M. M., Jensen, D. M., & Mathiesen, E. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1200 · Cited by 331
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citationAmiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307 · cited 2×
“47 This recommendation was later endorsed in an international consensus conference convened in Paris in 2017 18 and is now referenced as an example of a standardized CGM report in the ADA 2019 Standards of Care (page 75) 16 and an update to the AACE consensus on use of CGM. 48 Most of the CGM…”
The impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284
Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus
Epstein, F. H., Cryer, P. E., & Gerich, J. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130405 · Cited by 273
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
Allen, N. A., Fain, J. A., Braun, B., & Chipkin, S. R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.006 · Cited by 182
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US
FORD, E. S., COWIE, C. C., LI, C., HANDELSMAN, Y., & BLOOMGARDEN, Z. T. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00100.x · Cited by 165 · cited 1×
“Moreover,HbA1c is an unreliable measure in multiple settings; certain conditions such as anemia, 20 hemoglobin-opathies, 21 iron deficiency, 22 and pregnancy 23 can confound test results.”
Glucose Variability: A Review of Clinical Applications and Research Developments
Rodbard, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0092 · Cited by 154
Cox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. H., Schlundt, D. G., & Clarke, W. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989471 · Cited by 137
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Šoupal, J., Petruželková, L., Flekač, M., Pelcl, T., Matoulek, M., Daňková, M., Škrha, J., Svačina, Š., & Prázný, M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0171 · Cited by 126
Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Self-citationChoudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118
Novodvorsky, P., Bernjak, A., Chow, E., Iqbal, A., Sellors, L., Williams, S., Fawdry, R. A., Parekh, B., Jacques, R. M., Marques, J. L. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2177 · Cited by 111
Brod, M., Rana, A., & Barnett, A. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.743457 · Cited by 60
Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice
Kruger, D. F., Edelman, S. V., Hinnen, D. A., & Parkin, C. G. (2019) · The Diabetes Educator · doi:10.1177/0145721718818066 · Cited by 55 · cited 1×
“53 Retrospective analysis of CGM data using AGP, from real-time or masked CGM data, presents a more complete picture of glycemic management, providing critical metrics such as TIR, allowing evaluation of glycemic variability, and displaying glycemic patterns.”
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., & Kollman, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0362 · Cited by 42
Self-citationTime Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose Profile
Mullen, D. M., Bergenstal, R., Criego, A., Arnold, K. C., Goland, R., & Richter, S. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817740592 · Cited by 22 · cited 1×
“19 The ambulatory glucose profile (AGP) is a standardized, single-page glucose report designed to simplify analysis and interpretation of downloaded CGM data.”
Self-citation
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus
Lin, R., Brown, F., James, S., Jones, J., & Ekinci, E. (2021) · Diabetic Medicine · doi:10.1111/dme.14528 · Cited by 197
Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., & Xi, M. X. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108106 · Cited by 87
Self-citation
Metadata
- Authors
- Johnson, M. L., Martens, T. W., Criego, A. B., Carlson, A. L., Simonson, G. D., & Bergenstal, R. M.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2019-06
- Volume
- 21
- Issue
- S2
- Pages
- S2-17-S2-25
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2949826262
- Cited by
- 104
- References
- 40
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.